RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a chronic pulmonary disorder of unknown etiology with few treatment options. Although tetraspanins are involved in various diseases, their roles in fibrosis have not been determined. OBJECTIVES: To investigate the role of tetraspanin CD151 in pulmonary fibrosis. METHODS: CD151 knockout (KO) mice were studied by histological, biochemical, and physiological analyses and compared with wild-type mice and CD9 KO mice. Further mechanistic analyses were performed in vitro, in vivo, and on samples from patients with IPF. MEASUREMENTS AND MAIN RESULTS: A microarray study identified an enrichment of genes involved in connective tissue disorders in the lungs of CD151 KO mice, but not in CD9 KO mice. Consistent with this, CD151 KO mice spontaneously exhibited age-related pulmonary fibrosis. Deletion of CD151 did not affect pulmonary fibroblast functions but instead degraded epithelial integrity via attenuated adhesion strength on the basement membrane; CD151-deleted alveolar epithelial cells exhibited increased α-SMA expression with activation of p-Smad2, leading to fibrotic changes in the lungs. This loss of epithelial integrity in CD151 KO lungs was further exacerbated by intratracheal bleomycin exposure, resulting in severe fibrosis with increased mortality. We also observed decreased numbers of CD151-positive alveolar epithelial cells in patients with IPF. CONCLUSIONS: CD151 is essential for normal function of alveolar epithelial cells; loss of CD151 causes pulmonary fibrosis as a result of epithelial disintegrity. Given that CD151 may protect against fibrosis, this protein represents a novel target for the treatment of fibrotic diseases.
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a chronic pulmonary disorder of unknown etiology with few treatment options. Although tetraspanins are involved in various diseases, their roles in fibrosis have not been determined. OBJECTIVES: To investigate the role of tetraspanin CD151 in pulmonary fibrosis. METHODS:CD151 knockout (KO) mice were studied by histological, biochemical, and physiological analyses and compared with wild-type mice and CD9 KO mice. Further mechanistic analyses were performed in vitro, in vivo, and on samples from patients with IPF. MEASUREMENTS AND MAIN RESULTS: A microarray study identified an enrichment of genes involved in connective tissue disorders in the lungs of CD151 KO mice, but not in CD9 KO mice. Consistent with this, CD151 KO mice spontaneously exhibited age-related pulmonary fibrosis. Deletion of CD151 did not affect pulmonary fibroblast functions but instead degraded epithelial integrity via attenuated adhesion strength on the basement membrane; CD151-deleted alveolar epithelial cells exhibited increased α-SMA expression with activation of p-Smad2, leading to fibrotic changes in the lungs. This loss of epithelial integrity in CD151 KO lungs was further exacerbated by intratracheal bleomycin exposure, resulting in severe fibrosis with increased mortality. We also observed decreased numbers of CD151-positive alveolar epithelial cells in patients with IPF. CONCLUSIONS:CD151 is essential for normal function of alveolar epithelial cells; loss of CD151 causes pulmonary fibrosis as a result of epithelial disintegrity. Given that CD151 may protect against fibrosis, this protein represents a novel target for the treatment of fibrotic diseases.
Authors: Yoshito Takeda; Alexander R Kazarov; Catherine E Butterfield; Benjamin D Hopkins; Laura E Benjamin; Arja Kaipainen; Martin E Hemler Journal: Blood Date: 2006-10-05 Impact factor: 22.113
Authors: Chrishan S Samuel; Chongxin Zhao; Ross A D Bathgate; Courtney P Bond; Matthew D Burton; Laura J Parry; Roger J Summers; Mimi L K Tang; Edward P Amento; Geoffrey W Tregear Journal: FASEB J Date: 2002-11-01 Impact factor: 5.191
Authors: Vanja Karamatic Crew; Nicholas Burton; Alexander Kagan; Carole A Green; Cyril Levene; Frances Flinter; R Leo Brady; Geoff Daniels; David J Anstee Journal: Blood Date: 2004-07-20 Impact factor: 22.113
Authors: Xiao Mei Wang; Yingze Zhang; Hong Pyo Kim; Zhihong Zhou; Carol A Feghali-Bostwick; Fang Liu; Emeka Ifedigbo; Xiaohui Xu; Tim D Oury; Naftali Kaminski; Augustine M K Choi Journal: J Exp Med Date: 2006-12-18 Impact factor: 14.307
Authors: Yuanqin Yin; Xinyu Deng; Zeyi Liu; Lauren A Baldwin; Jason Lefringhouse; Jiayang Zhang; John T Hoff; Sonia F Erfani; Edmund B Rucker; Kathleen O'Connor; Chunming Liu; Yadi Wu; Binhua P Zhou; Xiuwei H Yang Journal: Cell Cycle Date: 2014 Impact factor: 4.534
Authors: Shannin C Zevian; Jessica L Johnson; Nicole E Winterwood; Katherine S Walters; Mary E Herndon; Michael D Henry; Christopher S Stipp Journal: Cancer Biol Ther Date: 2015-09-29 Impact factor: 4.742
Authors: Trenis D Palmer; Carlos H Martínez; Catalina Vasquez; Katie E Hebron; Celestial Jones-Paris; Shanna A Arnold; Susanne M Chan; Venu Chalasani; Jose A Gomez-Lemus; Andrew K Williams; Joseph L Chin; Giovanna A Giannico; Tatiana Ketova; John D Lewis; Andries Zijlstra Journal: Cancer Res Date: 2013-11-12 Impact factor: 12.701
Authors: Saaket Varma; Poornima Mahavadi; Satish Sasikumar; Leah Cushing; Tessa Hyland; Ann E Rosser; Daniela Riccardi; Jining Lu; Tanya V Kalin; Vladimir V Kalinichenko; Andreas Guenther; Maria I Ramirez; Annie Pardo; Moisés Selman; David Warburton Journal: Am J Physiol Lung Cell Mol Physiol Date: 2013-12-27 Impact factor: 5.464